Isodeoxyelephantopin, a novel sesquiterpene lactone, potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis through suppression of nuclear factor-kappaB (nf-kappaB) activation and nf-kappaB-regulated gene expression

Clin Cancer Res. 2006 Oct 1;12(19):5910-8. doi: 10.1158/1078-0432.CCR-06-0916.

Abstract

Purpose: Deoxyelephantopin (ESD) and isodeoxyelephantopin (ESI) are two sesquiterpene lactones derived from the medicinal plant Elephantopus scaber Linn. (Asteraceae). Although they are used for the treatment of a wide variety of proinflammatory diseases, very little is known about their mechanism of action. Because most genes that control inflammation are regulated by activation of the transcription factor nuclear factor-kappaB (NF-kappaB), we postulated that ESD and ESI mediate their activities through modulation of the NF-kappaB activation pathway.

Experimental design: We investigated the effect of ESI and ESD on NF-kappaB activation by electrophoretic mobility shift assay and NF-kappaB-regulated gene expression by Western blot analysis.

Results: We found that ESI suppressed NF-kappaB activation induced by a wide variety of inflammatory agents, including tumor necrosis factor (TNF), interleukin-1beta, phorbol 12-myristate 13-acetate, and lipopolysaccharide. The suppression was not cell type specific, and both inducible and constitutive NF-kappaB activation was blocked. ESI did not interfere with the binding of NF-kappaB to DNA but rather inhibited IkappaBalpha kinase, IkappaBalpha phosphorylation, IkappaBalpha degradation, p65 phosphorylation, and subsequent p65 nuclear translocation. ESI also suppressed the expression of TNF-induced NF-kappaB-regulated, proliferative, antiapoptotic, and metastatic gene products. These effects correlated with enhancement of apoptosis induced by TNF and suppression of TNF-induced invasion and receptor activator of NF-kappaB ligand-induced osteoclastogenesis.

Conclusion: Our results indicate that ESI inhibits NF-kappaB activation and NF-kappaB-regulated gene expression, which may explain the ability of ESI to enhance apoptosis and inhibit invasion and osteoclastogenesis.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Apoptosis / drug effects*
  • Blotting, Western
  • Cell Differentiation
  • Cell Movement / drug effects*
  • Electrophoretic Mobility Shift Assay
  • Enzyme Activation / drug effects
  • Humans
  • I-kappa B Kinase / metabolism
  • I-kappa B Proteins / metabolism
  • Immunoprecipitation
  • Interleukin-1 / pharmacology
  • Lactones / pharmacology*
  • Lipopolysaccharides / pharmacology
  • NF-KappaB Inhibitor alpha
  • NF-kappa B / antagonists & inhibitors*
  • NF-kappa B / genetics
  • NF-kappa B / metabolism
  • Neoplasms* / drug therapy
  • Neoplasms* / metabolism
  • Osteoclasts / cytology
  • Osteoclasts / drug effects
  • Osteoclasts / metabolism
  • Phosphorylation / drug effects
  • Sesquiterpenes / pharmacology*
  • Terpenes / pharmacology*
  • Tetradecanoylphorbol Acetate / pharmacology
  • Tumor Cells, Cultured
  • Tumor Necrosis Factor-alpha / metabolism
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • I-kappa B Proteins
  • Interleukin-1
  • Lactones
  • Lipopolysaccharides
  • NF-kappa B
  • NFKBIA protein, human
  • Sesquiterpenes
  • TNF protein, human
  • Terpenes
  • Tumor Necrosis Factor-alpha
  • elephantopin
  • NF-KappaB Inhibitor alpha
  • I-kappa B Kinase
  • Tetradecanoylphorbol Acetate